Head-to-head evidence
SPY001 vs vedolizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: α4β7 integrin · full Ulcerative Colitis pipeline
SPY001
Developed by Spyre Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07012395 (registry estimate)
vedolizumab · Entyvio
Marketed by Takeda Pharmaceutical Company
NCT00783718 · Phase 3 · completed
Randomized, triple-blind, placebo-controlled, adequately powered (n=895) phase 3 design with hard clinical endpoints (Mayo score-based clinical response/remission), and both primary endpoint comparisons reached statistical significance in the favorable direction (Induction: p<0.0001, RD 21.7%; Maintenance: p<0.0001 for both dose arms vs placebo) — meeting the 'strong' test.
Next expected readout: May 2027 · NCT06581328 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SPY001's landscape · vedolizumab's landscape